Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment

Rhea-AI Summary

Pluri (Nasdaq, TASE: PLUR) appointed shareholder Alejandro Weinstein as Chairman on Dec 9, 2025, while prior Chairman Zami Aberman will transition to Vice Chairman. Weinstein’s ownership is expected to rise to approximately 30%, and he brings a track record including a prior company sale to Abbott for $2.9 billion.

Pluri entered a private placement where an entity beneficially owned by Weinstein will purchase 625,000 common shares plus warrants for an additional 625,000 shares at a combined purchase price of $4, generating gross proceeds of ~$2.5 million. Warrants exercise price is $4.25, exercisable immediately until June 30, 2026. Proceeds are for general working capital.

Positive

• Alejandro Weinstein appointed Chairman
• Ownership to ~30% signaling strong insider conviction
• $2.5 million gross proceeds from private placement
• 625,000 warrants exercisable immediately until June 30, 2026
• Weinstein led prior $2.9B exit at CFR Pharmaceuticals

Negative

• Warrants exercisable until June 30, 2026 could increase share count if exercised

Key Figures

M&A transactions over 20 Number of M&A deals Alejandro Weinstein participated in

Exit value more than $5 billion Aggregate exit value across healthcare, biotechnology and nutrition

Ownership stake approximately 30% Expected Alejandro Weinstein ownership on issued and outstanding basis

Shares purchased 625,000 shares Common shares in private placement

Warrants issued 625,000 warrants Warrants to purchase additional common shares

Purchase price $4 Combined purchase price per share plus warrant in private placement

Warrant exercise price $4.25 per share Exercise price of private placement warrants

Gross proceeds approximately $2.5 million Aggregate gross proceeds from private placement

Market Reality Check

$3.13 Last Close

Volume Relative volume is low with 18,659 shares vs 59,093 20-day average (relative volume 0.32). low

Technical Shares at $3.13 are trading below the 200-day MA of $4.56 and close to the 52-week low of $3.10.

Peers on Argus 1 Up

Biotech peers show mixed moves: ESLA up 2.5%, IPSC up 7.79%, while LVTX is down 3.87%. Momentum scanner only flags one peer (SNTI up 20.5%), suggesting PLUR’s leadership change and insider financing are more company-specific than sector-driven.

Common Catalyst Several peers, including IPSC and PEPG, also reported board or senior management-related news, pointing to a governance and leadership-focus theme in the biotech space.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 13	Industry awards	Positive	-6.1%	Multiple industry honors and awards recognizing Pluri and its subsidiaries.
Nov 11	Commercial partnership	Positive	+6.2%	Launch of Cellav subsidiary and skincare collaboration with Miss Universe Skincare.
Nov 10	Strategic collaborations	Positive	+18.5%	Global collaborator-funded MVP programs for cultivated meat, cacao, and coffee.
Oct 08	Food-tech partnership	Positive	-5.1%	Three-phase collaboration to advance cell-based coffee manufacturing in Mexico.

Pattern Detected

Recent news with positive strategic or partnership themes has produced mixed reactions, with roughly half of events followed by gains and half by declines, indicating inconsistent market response to ostensibly positive catalysts.

Recent Company History

Over the last few months, Pluri reported multiple strategic collaborations and recognitions. On Nov 10, 2025, international food and agriculture collaborations drove a 18.54% move higher, and a skincare partnership on Nov 11, 2025 was followed by a 6.15% gain. By contrast, industry awards on Nov 13, 2025 and a coffee collaboration on Oct 8, 2025 coincided with declines of 6.07% and 5.12%, respectively. Today’s chairman appointment plus insider financing fits the pattern of strategic, value-unlocking initiatives.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-17

$724,686 registered capacity

An active S-3 shelf filed on 2025-09-17 covers resale of 3,425,488 shares by selling shareholders. Pluri would not receive proceeds from those resales but could receive approximately $724,686 if outstanding warrants and pre-funded warrants are exercised for cash at disclosed exercise prices. The shelf has reported 0 usages so far, and the registration is not yet effective.

Market Pulse Summary

This announcement combines a governance shift with fresh insider capital. Alejandro Weinstein becomes chairman and is expected to lift his stake toward 30%, while a private placement of 625,000 shares plus 625,000 warrants at a $4 combined price brings in about $2.5 million. Historically, Pluri’s strategic partnerships and recognitions have produced mixed price follow-through. Investors may watch how this added capital, the active S-3, and warrant structures interact with execution on commercialization plans.

Key Terms

m&a transactions financial

"participation in over 20 M&A transactions and more than $5 billion in exits"

M&A transactions are deals in which one company buys, merges with, or combines operations with another—this includes purchases of stock, assets, or complete mergers. They matter to investors because such deals can quickly change a company’s size, costs, revenue and risk profile; like two households merging finances or one buying another’s business, M&A can boost growth or create hidden costs, affecting share prices, debt levels and future profits.

warrants financial

"together with warrants to purchase up to an additional 625,000 common shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

securities purchase agreement financial

"Pluri has entered into a Securities Purchase Agreement with an entity"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

private placement financial

"common shares in a private placement, at a combined purchase price of $4"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

regulation d regulatory

"and/or Regulation D promulgated thereunder, or applicable state securities laws"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

registration statement regulatory

"except pursuant to an effective registration statement or an applicable exemption"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

• Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.
• Weinstein’s ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri’s asset base, its valuation potential, and its long term strategy.

HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the Board of Directors. The appointment reflects the Board’s view that Mr. Weinstein brings a decisive, business driven perspective that aligns with Pluri’s objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company’s underlying assets.

“I am honored to take on the role of Chairman and am fully committed to make the strategic changes needed for driving Pluri into its next stage of growth,” said Alejandro Weinstein. “Pluri has a strong platform, promising commercial pathways, and a portfolio of assets that I believe hold significant untapped potential. Together with the management team, I look forward to building on the Company’s solid foundation, advancing key priorities, and further strengthening strategic initiatives that can unlock the substantial value inherent in our underlying assets, and drive long-term value. I also want to thank Mr. Aberman for his long-standing leadership and meaningful contribution to Pluri’s foundation.”

Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman.

As part of this leadership evolution, Mr. Zami Aberman, who has served as Pluri’s Chairman for two decades, will transition into the role of Vice Chairman and continue to support the Company’s strategic direction.
“It has been a privilege to serve as Chairman and to help guide Pluri through key stages of its development,” says outgoing Chairman Zami Aberman.
“Alejandro’s increased involvement reflects the strong potential ahead and his approach to value creation. As I transition into the role of Vice Chairman, I look forward to supporting Pluri’s continued progress and ensuring a smooth leadership transition.”

Yaky Yanay, Chief Executive Officer and President of Pluri, commented: “Mr. Weinstein’s increased investment and appointment as Chairman reflect a clear belief in our direction and mark the beginning of a new phase for Pluri. I want to sincerely thank Mr. Aberman for his leadership over the past two decades and for his continued support as Vice Chairman. With Mr. Weinstein now taking the Chairman role, we are focused on sharpening execution, accelerating commercialization, and unlocking the significant value within our platform and ventures for the benefit of our shareholders and strengthening our position for the years ahead.”

In addition to this leadership transition, Pluri has entered into a Securities Purchase Agreement with an entity beneficially owned by Mr. Weinstein. Pursuant to the agreement, the investor will purchase 625,000 Pluri common shares, together with warrants to purchase up to an additional 625,000 common shares in a private placement, at a combined purchase price of $4. The warrants have an exercise price of $4.25 per share, are exercisable immediately and will be exercisable until June 30, 2026. The transaction is expected to generate aggregate gross proceeds of approximately $2.5 million. Pluri intends to use the proceeds from the private placement for general working capital.

The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Pluri Inc:

Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions.

The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

Forward-Looking Statements

This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its objectives of strengthening market positioning, sharpening its commercial execution, and accelerating recognition and realization of the value embedded in its underlying assets, that Pluri has real commercial opportunities and a portfolio of assets that are undervalued by the market, that the Company’s ventures represent meaningful strategic potential, Pluri’s focus on sharpening execution, advancing commercialization and building long-term value for its shareholders, and the expected use of proceeds from the private placement. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.

Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com

FAQ

What change did Pluri announce on December 9, 2025 regarding board leadership?

Pluri appointed Alejandro Weinstein as Chairman and moved Zami Aberman to Vice Chairman.

How will Alejandro Weinstein’s stake in PLUR change after the transaction?

Weinstein’s ownership is expected to increase to approximately 30% on an issued and outstanding basis.

What are the terms of the private placement tied to the PLUR leadership change?

An entity beneficially owned by Weinstein will buy 625,000 shares plus warrants for 625,000 shares at a combined price of $4, raising ~$2.5M.

What is the warrants exercise price and expiry in Pluri’s private placement?

Warrants have an exercise price of $4.25, are exercisable immediately, and expire on June 30, 2026.

How does Pluri intend to use proceeds from the private placement (PLUR)?

Pluri intends to use the proceeds for general working capital.

Does Alejandro Weinstein have prior experience leading value‑creation in healthcare?

Yes; Weinstein helped scale companies including a CFR Pharmaceuticals sale to Abbott for $2.9B.